Application of USP 665 data to support qualification of single use systems

 

With the publication of the new chapters in USP <665> on September 1st join Ken Wong from Sanofi Pasteur, Desmond Hunt from United States Pharmacopeia and James Hathcock from Pall Biotech to get the latest updates.

 

Participants will learn:

 

  • About the USP <665> standardized extraction solution protocol for manufacturing components and systems

  • What is new and what has changed in USP <665> and <1665> (as of September 2020)

  • The top issues influencing the alignment of the BioPhorum extractables protocol and USP <665>

  • What level of data end-users can expect to see

  • How to apply USP <665> data sets to support risk assessment and qualification of single-use systems

  • The opportunities ahead for simplifying the adoption of single-use technologies

Don’t miss this free BioPharma Asia webinar to hear from subject matter experts serving on the USP and BPOG panels!

Speakers

ken wong

Ken Wong

 

Deputy Director of Process Technology

Sanofi Pasteur

Ken Wong is a Deputy Director of Process Technology Platform at Sanofi Pasteur. Serving as the Swiftwater site extractables and leachables (E&L) SME but also provide E&L supports to all global sites. In the last 10 years, he has been heavily involved with Single-Use Technology and actively participating in Disposable workstreams of BioPhorum Operations Group (BPOG), the USP <665> Expert Panel and the ELSIE material working group.

dr. desmond hunt

Dr. Desmond G. Hunt

 

‌Principal Scientific Liaison

USP

Dr. Desmond G. Hunt has been with USP since 2005 and holds the position of Principle Scientific Liaison in the Compendial Science Group-General Chapters. He is the scientific liaison to the Packaging and Distribution and Dosage Forms Expert Committees, where he works to develop and revise USP Standards. He participates on several industry Working Groups and Technical Committees related to his areas of expertise.

James Hathcock, PhD

James Hathcock, PhD

 

‌Senior Director of Regulatory and Validation

Pall Biotech

James Hathcock, PhD is Senior Director of Regulatory and Validation Strategy at Pall Biotech, which includes responsibility for E&L characterization strategy to support the safe and successful end-user implementation of technologies enabling pharmaceutical manufacturing. He is an active member of ASTM, ASME-BPE, PDA, ISPE, BPSA, Biophorum-supplier phorum as well a USP <665> expert panel member.

Application of USP 665 data to support qualification of single use systems

icon image

Explore the Pall Regulatory Support Portal

Download a sample extractables report, get our impurities risk assessment calculator, explore the list of available extractables reports for Pall-manufactured components and much more!

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
May 2021
Overcome Exosome Production Challenges

Biotech | Pall Corporation webinar series

This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters. Scroll down to see a transcript of the webinar question and answer session.

 

Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.

David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.

Participants will be able to:

 

  • Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
  • Understand how an integrated end to end platform delivers highly   purified and consistently-sized exosomes
  • Discover an innovative cGMP scalable manufacturing platform for   exosomes
Watch